FSFederico Storni

Federico Storni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Federico Storni has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rapid, Label-Free Cancer Detection in Fresh Pancreatic Tissue Using Deep Learning and Multispectral Mueller Matrix Polarimetry

    by Paulo Sampaio, Davide Scandella, C. H. Lucas Patty, Pablo Márquez-Neila, Heather DiFazio, Martin Wartenberg, Federico Storni, Brice-Olivier Demory, Daniel Candinas, Aurel Perren, et al.

    Frozen section (FS) tissue assessment is essential for guiding intraoperative surgical decision-making in oncology, particularly in procedures such as pancreatic ductal adenocarcinoma (PDAC) resections, where margin status critically impacts patient survival. The current gold standard, (FS), while widely used, suffers from notable limitations, including tissue artifacts, dependence on specialized expertise, and slow turnaround times, resulting in sampling errors and false negatives. To address these challenges, we present a novel approach for automatic cancer identification in fresh tissue biopsies using mul tispectral Mueller Matrix (MM) polarimetry. Our custom-built multispectral MM polarimeter captures polarization-resolved imaging across multiple wavelengths, enabling pixel-level analysis of tissue microstructure without staining or histology sectioning. Our approach thus allows for assessments in quasi-real time. From these, we propose a deep learning model that uses MM data collected from PDAC patients to distinguish cancerous from non-cancerous biopsies to assess samples automatically. Experimental results demonstrate classification performance comparable to RFS assessments performance found in clinical routine, with enhanced diagnostic speed. We show that our approach is consistent and coherent against pixel-wise annotations from histology slides. This study highlights the potential of MM polarimetry combined with machine learning as a viable, label-free alternative for real-time intraoperative cancer detection.

  • Open Access

    Early Complications in Kidney Donors and Course of Health-related Quality of Life 12 mo After Donation: An Analysis of the Swiss Organ Living-Donor Health Registry

    by Charlotte Brügger, Zoé Hunkeler, Matthias Diebold, Joana Krättli, Irene Lic Phil Geiger, Caroline Wehmeier, Thomas Wolff, Bruno Vogt, Federico Storni, Dela Golshayan, et al.

    Background.: Since 1998, the Swiss Organ Living-Donor Health Registry (SOL-DHR) has recorded peri- and postoperative complications of living kidney (LK) donors, as reported by all Swiss transplant centers and has collected follow-up data prospectively. Methods.: We analyzed the early complications of 2379 consecutive individuals who donated a kidney between January 1998 and June 2022 and assessed their health-related quality of life (HRQoL) 1 y after donation. Results.: In total, 447 early complications in 404/2379 LK donors (17.0%) were reported to the SOL-DHR. The frequency of donors with major complications (ie, Dindo-Clavien classification 3/4) was 2.4%. In total, 31 donors needed reoperation, and in 13/31 (42%), donors reoperation was necessary because of bleeding complications. Independent risk factors for major early complications were older donor age (P = 0.005) and type of surgical approach (ie, the laparoscopic retroperitoneal compared with laparoscopic transabdominal surgery; P = 0.01), but not sex. We observed a U-shaped association of body mass index, where very low/high body mass indexes had higher odds of major early complications, without reaching statistical significance. Although HRQoL was affected by kidney donation, 96.5% of donors indicated that they would donate their kidney again. The only independent risk factor for low HRQoL based on mental health scores was worsening EB after living kidney donation (P < 0.0001). Conclusions.: Overall, living kidney donation is a safe procedure, however, donor age and type of surgical approach affect the risk of complications. A decline in emotional bonding with the recipient after donation may worsen the quality of life of the donor.


  • Open Access

    The next generation virus‐like particle platform for the treatment of peanut allergy

    by Jan M. Sobczak, Pascal S. Krenger, Federico Storni, Mona O. Mohsen, Ina Balke, Gunta Reseviča, Matthew D. Heath, Thalia L. Carreno Velazquez, Matthias F. Kramer, Callum J. W. Scott, et al.

    Background: Allergy to peanut is one of the leading causes of anaphylactic reactions among food allergic patients. Immunization against peanut allergy with a safe and protective vaccine holds a promise to induce durable protection against anaphylaxis caused by exposure to peanut. A novel vaccine candidate (VLP Peanut), based on virus‐like particles (VLPs), is described here for the treatment of peanut allergy.Methods and Results: VLP Peanut consists of two proteins: a capsid subunit derived from Cucumber mosaic virus engineered with a universal T‐cell epitope (CuMVTT) and a CuMVTT subunit fused with peanut allergen Ara h 2 (CuMVTT‐Ara h 2), forming mosaic VLPs. Immunizations with VLP Peanut in both naïve and peanut‐sensitized mice resulted in a significant anti‐Ara h 2 IgG response. Local and systemic protection induced by VLP Peanut were established in mouse models for peanut allergy following prophylactic, therapeutic, and passive immunizations. Inhibition of FcγRIIb function resulted in a loss of protection, confirming the crucial role of the receptor in conferring cross protection against peanut allergens other than Ara h 2.Conclusion: VLP Peanut can be delivered to peanut‐sensitized mice without triggering allergic reactions, while remaining highly immunogenic and offering protection against all peanut allergens. In addition, vaccination ablates allergic symptoms upon allergen challenge. Moreover, the prophylactic immunization setting conferred the protection against subsequent peanut‐induced anaphylaxis, showing the potential for preventive vaccination. This highlights the effectiveness of VLP Peanut as a prospective break‐through immunotherapy vaccine candidate toward peanut allergy. VLP Peanut has now entered clinical development with the study PROTECT.


  • Inside Front Cover

    by Guido Stirnimann, Thomas Berg, Laurent Spahr, Stefan Zeuzem, Stuart McPherson, Frank Lammert, Federico Storni, Vanessa Banz, Jana Babatz, Victor Vargas, et al.

  • Open Access

    Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump

    by Guido Stirnimann, Thomas Berg, Laurent Spahr, Stefan Zeuzem, Stuart McPherson, Frank Lammert, Federico Storni, Vanessa Banz, Jana Babatz, Victor Vargas, et al.

    Background and aims: Patients with cirrhotic refractory ascites ineligible for transjugular intrahepatic shunt (TIPSS) have limited treatment options apart from repeated large volume paracentesis. The alfapump® is an implantable device mobilizing ascites from the peritoneal cavity to the bladder, from where it can be excreted. The aim of this observational cohort study was to prospectively investigate safety and efficacy of the device in a real‐world cohort with cirrhotic refractory ascites and contraindications for TIPSS.Methods: A total of 106 patients received an implant at 12 European centres and were followed up for up to 24 months. Complications, device deficiencies, frequency of paracentesis, clinical status and survival were recorded prospectively.Results: Approximately half of the patients died on‐study, about a quarter was withdrawn because of serious adverse events leading to explant, a sixth were withdrawn because of liver transplant or recovery, and nine completed follow‐up. The most frequent causes of on‐study death and complication‐related explant were progression of liver disease and infection. The device reduced the requirement for large‐volume paracentesis significantly, with more than half of patients not having required any post‐implant. Survival benefits were not observed. Device‐related reinterventions were predominantly caused by device deficiencies. A post‐hoc comparison of the first 50 versus the last 50 patients enrolled revealed a decreased reintervention rate in the latter, mainly related to peritoneal catheter modifications.Conclusions: The device reduced paracentesis frequency in a real‐world setting. Technical complications were successfully decreased by optimization of management and device modification (NCT01532427).


  • Open Access

    A Metabolomic Analysis of Cirrhotic Ascites

    by Diren Beyoğlu, Cedric Simillion, Federico Storni, Andrea De Gottardi, Jeffrey R. Idle

    Ascites is a common complication of decompensated liver cirrhosis, and yet relatively little is known about its biochemical composition. We conducted two metabolomic investigations, comparing the profile of ascites from 33 cirrhotic patients and postoperative peritoneal drainage fluid from 33 surgical patients (Experiment 1). The profile of paired ascites and plasma was also compared in 17 cirrhotic patients (Experiment 2). Gas chromatography–mass spectrometry-based metabolomics identified 29 metabolites that significantly characterized ascites fluid, whether postoperative drainage fluid or plasma were used as controls. Ten elevated amino acids (glutamine, proline, histidine, tyrosine, glycine, valine, threonine, methionine, lysine, phenylalanine) and seven diminished lipids (laurate, myristate, palmitate, oleate, vaccenate, stearate, cholesterol) largely comprised the cirrhotic ascites metabolomic phenotype that differed significantly (adjusted p < 0.002 to 0.03) from peritoneal drainage fluid or plasma. The pattern of upregulated amino acids in cirrhotic ascites did not indicate albumin proteolysis by peritoneal bacteria. Bidirectional clustering showed that the more severe the cirrhosis, the lower the lipid concentration in ascitic fluid. The metabolomic compartment of ascites in patients with decompensated cirrhosis is characterized by increased amino acids and decreased lipids. These novel findings have potential relevance for diagnostic purposes.


  • Open Access

    Outcome in patients with open abdomen treatment for peritonitis: a multidomain approach outperforms single domain predictions

    by Sven Petersen, Markus Huber, Federico Storni, Gero Puhl, Alice Deder, Axel Prause, Joerg C. Schefold, Dietrich Doll, Patrick Schober, Markus M. Luedi

    Numerous patient-related clinical parameters and treatment-specific variables have been identified as causing or contributing to the severity of peritonitis. We postulated that a combination of clinical and surgical markers and scoring systems would outperform each of these predictors in isolation. To investigate this hypothesis, we developed a multivariable model to examine whether survival outcome can reliably be predicted in peritonitis patients treated with open abdomen. This single-center retrospective analysis used univariable and multivariable logistic regression modeling in combination with repeated random sub-sampling validation to examine the predictive capabilities of domain-specific predictors (i.e., demography, physiology, surgery). We analyzed data of 1,351 consecutive adult patients (55.7% male) who underwent open abdominal surgery in the study period (January 1998 to December 2018). Core variables included demographics, clinical scores, surgical indices and indicators of organ dysfunction, peritonitis index, incision type, fascia closure, wound healing, and fascial dehiscence. Postoperative complications were also added when available. A multidomain peritonitis prediction model (MPPM) was constructed to bridge the mortality predictions from individual domains (demographic, physiological and surgical). The MPPM is based on data of n = 597 patients, features high predictive capabilities (area under the receiver operating curve: 0.87 (0.85 to 0.90, 95% CI)) and is well calibrated. The surgical predictor “skin closure” was found to be the most important predictor of survival in our cohort, closely followed by the two physiological predictors SAPS-II and MPI. Marginal effects plots highlight the effect of individual outcomes on the prediction of survival outcome in patients undergoing staged laparotomies for treatment of peritonitis. Although most single indices exhibited moderate performance, we observed that the predictive performance was markedly increased when an integrative prediction model was applied. Our proposed MPPM integrative prediction model may outperform the predictive power of current models.


  • Open Access

    Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens

    by Federico Storni, Andris Zeltins, Ina Balke, Matthew D. Heath, Matthias F. Kramer, Murray A. Skinner, Lisha Zha, Elisa Roesti, Paul Engeroff, Lukas Muri, et al.


  • Open Access

    A Single Monoclonal Antibody against the Peanut Allergen Ara h 2 Protects against Systemic and Local Peanut Allergy

    by Federico Storni, Gustavo Cabral-Miranda, Elisa Roesti, Lisha Zha, Paul Engeroff, Andris Zeltins, Mark Cragg, Monique Vogel, Martin F. Bachmann

    Background: Peanut allergy is the most prevalent and dangerous food allergy. Peanuts consist of a large number of different allergens and peanut-allergic patients are frequently sensitized to multiple allergens. Hence, conventional desensitization approaches aim at targeting as many allergens as possible. Methods: The monoclonal anti-Ara h 2 antibody (mAb) was produced by hybridoma cells derived from WT BALB/c mice after immunization with a vaccine based on virus-like particles coupled to Ara h 2. BALB/c mice were sensitized intraperitoneally with peanut extract absorbed to alum and mAbs were applied i.v. Challenge was performed the next day with the whole peanut extract intravenously and via skin prick test. Results: Here we show in peanut-allergic mice that a single high-affinity mAb specific for Ara h 2 is able to block systemic and local allergic reactions induced by the complex peanut extract. We confirm in vitro binding of the mAb to the inhibitory low-affinity FcγRIIb receptor using a sensitive biosensor and demonstrate in vivo that protection was dependent on FcγRIIb. Conclusion: A single mAb specific for Ara h 2 is able to improve local and systemic allergic symptoms induced by the whole allergen mixture.


  • Open Access

    Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus

    by Elisa S. Roesti, Christina N. Boyle, Daniel T. Zeman, Marcos Sande-Melon, Federico Storni, Gustavo Cabral-Miranda, Alexander Knuth, Thomas A. Lutz, Monique Vogel, Martin F. Bachmann

    Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by insulin resistance and insufficient insulin secretion to maintain normoglycemia. The majority of T2DM patients bear amyloid deposits mainly composed of islet amyloid polypeptide (IAPP) in their pancreatic islets. These—originally β-cell secretory products—extracellular aggregates are cytotoxic for insulin-producing β-cells and are associated with β-cell loss and inflammation in T2DM advanced stages. Due to the absence of T2DM preventive medicaments and the presence of only symptomatic drugs acting towards increasing hormone secretion and action, we aimed at establishing a novel disease-modifying therapy targeting the cytotoxic IAPP deposits in order to prevent the development of T2DM. We generated a vaccine based on virus-like particles (VLPs), devoid of genomic material, coupled to IAPP peptides inducing specific antibodies against aggregated, but not monomeric IAPP. Using a mouse model of islet amyloidosis, we demonstrate in vivo that our vaccine induced a potent antibody response against aggregated, but not soluble IAPP, strikingly preventing IAPP depositions, delaying onset of hyperglycemia and the induction of the associated pro-inflammatory cytokine Interleukin 1β (IL-1β). We offer the first cost-effective and safe disease-modifying approach targeting islet dysfunction in T2DM, preventing pathogenic aggregates without disturbing physiological IAPP function.